Takeshima H, Akaza H
Dept. of Urology, University of Tsukuba, Japan.
Gan To Kagaku Ryoho. 1998 Feb;25(3):345-51.
Clinical efforts to spare bladder function even in the case of muscle invasive recurrent bladder cancer is taking. Early detection of recurrence is essential for bladder sparing, and both urinary NMP22 and BTA are thought to have potency to detect recurrence of bladder cancer earlier than urinary cytology. Intravesical administration of BCG for superficial bladder cancer and intraarterial injection of chemoagents (Methotrexate and Cisplatin) with radiation for muscle invasive bladder cancer are thought to play important roles in sparing the bladder. Early detection of recurrent prostate cancer is becoming easier by ultrasensitive PSA assay. Though the value of early detection of recurrence is not proven since the benefits of early hormonal treatment have not yet been established, that should be a good indicator to evaluate new and coming treatments and play a important role to develop an effective treatment for recurrent prostate cancer.
即使对于肌肉浸润性复发性膀胱癌，目前也正在进行保留膀胱功能的临床努力。复发的早期检测对于保留膀胱至关重要，尿NMP22和BTA被认为比尿细胞学检查更有能力更早地检测出膀胱癌的复发。对于浅表性膀胱癌，膀胱内灌注卡介苗，对于肌肉浸润性膀胱癌，动脉内注射化疗药物（甲氨蝶呤和顺铂）并联合放疗，被认为在保留膀胱方面发挥着重要作用。通过超敏PSA检测，复发性前列腺癌的早期检测变得更加容易。尽管由于早期激素治疗的益处尚未确立，复发早期检测的价值尚未得到证实，但这应该是评估新出现治疗方法的一个良好指标，并在开发复发性前列腺癌的有效治疗方法方面发挥重要作用。
